Latest news with #lifesciences
Associated Press
4 days ago
- Business
- Associated Press
Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Hey, biotech folks! Whether you're a lab whiz itching to land your next role in drug discovery or a hiring manager hunting for the perfect candidate to boost your startup, the life sciences world is buzzing with potential. But, real talk—finding the right job or talent in this fast-moving industry can feel like trying to spot a single cell under a microscope. Overwhelming, right? That's were specialized recruitment websites swoop in like career superheroes. I've rounded up the five best platforms to help you navigate the biotech job maze, and guess what? SIRE Searchis leading the charge with its sharp, tailored approach. Let's dive in and see why these sites are your new allies for crushing it in biotech! 1. – Your Career's Guide A recruitment platform that feels like it knows you better than your lab partner. That's SIRE Searchin a nutshell. Based in Haarlem, Netherlands—a charming spot, by the way—SIRE has been shaking up the life sciences scene since 2012. Whether you're into pharmaceuticals, medical devices, or even fast-moving consumer goods (yep, they've got that covered), SIRE's the place to find your next career win. Their reverse recruitment approach is like a secret weapon. Instead of tossing a pile of job listings your way, they do the heavy lifting first. Using data and market insights, their team—packed with recruiters who actually get biotech—handpicks roles that match your skills and goals. One Trustpilot reviewer raved, 'SIRE landed me a job that's spot-on for my expertise. They were quick and genuinely cared!' With a 4-star rating, they're clearly hitting the mark. 2. – The U.S. Biotech Hub Let's zip over to the States for BioSpace, a heavyweight for biotech and pharma jobs. With over 4,000 active listings, this sites like a treasure chest for anyone looking to dive into or climb higher in the U.S. biotech scene. From lab techs to execs, BioSpace has roles for every step of your journey. What's the deal with BioSpace? It's more than a job board—it's a whole community. You can narrow down searches by niche (like gene therapy or clinical trials) or location, so you're not stuck scrolling through irrelevant posts. They also dish out extras like industry updates, career tips, and their 'Best Places to Work' report, which is like a VIP list for biotech companies. The downside? It's mostly U.S.-focused, so it doesn't have SIRE's global reach. But for North American job seekers, BioSpace is a goldmine. 3. – Your Global Career Connector Dreaming of a biotech career that takes you worldwide? Meet Preclinical. With offices in places like the UK, Singapore, and the U.S., this platform hooks up candidates with roles in everything from drug development to regulatory affairs. It's like having a friend who knows the hottest jobs on every continent. Proclinical's strength is precision. Their recruiters dig into what employers need—skills, culture, the whole package—and match that with a huge candidate network. It's like they're playing career matchmaker, and they're good at it. They don't have SIRE's data-driven reverse recruitment trick, but their global scope is a big win for anyone wanting to think beyond borders. Plus, their blog's full of practical tips, like how to tweak your CV or nail an interview, which is super handy. 4. – The Science Lover's Hangout Next up is New Scientist Jobs, the friendly, all-purpose spot for science buffs. It covers a range of fields, but its biotech section is packed with roles in areas like vaccine research or molecular biology. Whether you're in Europe, the U.S., or elsewhere, this platform's global vibe makes it a welcoming place to explore. Why's it worth your time? It's easy to navigate, with filters to zero in on jobs by expertise or location. Their blog's a gem, too, with career advice and industry scoops that keep you in the loop. It's not as biotech-focused as SIRE, so you might need to sift a bit to find the right role. But if you're curious and love poking around, New Scientist Jobs is a solid bet. 5. – The Job-Finding Shortcut Last up is BioPharmGuy, the quirky underdog we're rooting for. Instead of hosting job listings, it points you straight to biotech company career pages, helping you dodge crowded job boards and find hidden opportunities. It's like a map of buried treasure. You can search by region or niche—like cell therapy or diagnostics—which makes it easy to target your sweet spot. The catch? It's more of a DIY experience, so you won't get the hands-on support you'd find with SIRE's recruiters. But for those who enjoy a bit of career sleuthing, BioPharmGuy is a clever tool to stand out. Why SIRE Search Takes the Crown? Let's give a shoutout to SIRE Searchfor stealing the show. Their reverse recruitment strategy is like having a career coach who's always one step ahead. By tapping into data and market trends, they find roles that fit you like a perfectly calibrated pipette. Their recruiters are biotech enthusiasts who speak your language and genuinely care about your next step. SIRE's focus on Europe—where biotech is thriving—gives them the edge, with connections to everyone from tiny startups to massive corporations. One candidate on Trustpilot said, 'SIRE made my job search feel effortless. They found me a role that's exactly where I want to be.' Employers love them, too, thanks to their knack for delivering candidates who nail both the skills and the vibe. Whether you're after a temp role or a corner office, SIRE's your partner in crime. 5 Tips to Nail Your Biotech Job Hunt Ready to hit these websites and land your dream role? Here's how to make it happen: Let's Wrap It Up The biotech world is full of possibilities, and these websites are your key to unlocking them. SIRE Searchleads the pack with its smart, personalized approach and deep love for life sciences. BioSpace, Preclinical, New Scientist Jobs, and BioPharmGuy are also stellar, each bringing their spark to the table. So, spruce up that resume, dive into these platforms, and get ready to make waves in biotech. Your next big opportunity is out there—grab it! Media Contact Company Name: Sire Search Email: Send Email Address:Staten Bolwerk City: 12011 MK Haarlem Country: Netherlands Website: Press Release Distributed by To view the original version on ABNewswire visit: Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Yahoo
02-06-2025
- Business
- Yahoo
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence LONDON, June 2, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions. As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence and Derwent Innovation Index. By bringing together world-class data and insights from academic research and the life sciences and healthcare sectors, the agreement empowers researchers and practitioners at all levels — including scholars, policy advisors, biomedical scientists and healthcare professionals — to conduct innovative research, develop new treatments, improve patient care, and inform policy decisions. It provides broad access to critical information, advancing evidence-based discovery, education and decision-making across disciplines. Matti Shem Tov, Chief Executive Officer, Clarivate, said: "This expanded partnership with CAPES is a powerful example of how strategic collaboration can accelerate research and innovation on a national scale. Brazil has made remarkable progress in advancing scientific excellence and global collaboration. We're proud to support this momentum by providing trusted data, insights, and technology to researchers across the country — from early discovery through impact assessment. Our shared commitment to expanding access and fostering innovation will continue to shape the future of research in Brazil and beyond." Denise Pires de Carvalho, President, CAPES, said: "Brazil is experiencing a moment of growing scientific output beyond its major urban centers, with resources now being distributed in a more equitable and democratic way to boost productivity across all regions. This collaboration with Clarivate enables us to better understand the scientific production profile of Brazilian institutions and supports more informed investment decisions to reduce regional disparities, which remains a significant national challenge. Many researchers in the North, Northeast and Center-West have limited access to the resources needed to give visibility to their work and expanding that access can make a meaningful difference." The renewed partnership reflects a shared commitment to democratizing access to critical scientific information and enabling data-driven research excellence. Through Web of Science, Journal Citation Reports, and Derwent Innovation Index, academic institutions and government agencies gain deeper visibility into global research trends, publication impact, and innovation pathways — supporting policy development, institutional benchmarking, and scholarly advancement. Complementing these capabilities, expanded access to Cortellis Drug Discovery Intelligence equips Brazil's life sciences community — including postgraduate students, faculty, and biomedical researchers — with comprehensive insights across biology, pharmacology, and chemistry. From disease understanding and drug interactions to clinical studies and intellectual property, users can more efficiently navigate the full R&D lifecycle and accelerate decision-making in high-impact research areas. By significantly expanding access to trusted research and innovation tools, this agreement supports CAPES' mission to reduce regional disparities and foster inclusive academic excellence. Institutions from across Brazil — from leading urban universities to those in underserved and remote regions — can now leverage high-quality data to strengthen postgraduate programs, accelerate innovation, and elevate the global visibility of Brazilian research. Clarivate values its collaboration with CAPES on this initiative to help shape a more connected, informed and future-ready research ecosystem across Brazil, and stands as a resource for academic consortia worldwide seeking to expand access to trusted research, data and insights. To learn more about this partnership and the solutions now available to CAPES institutions, visit here. Notes to editors According to the most recent Institute for Scientific Information G20 research and innovation scorecard: Around 40% of Brazilian research output is internationally collaborative, with many strong bilateral partnerships with the United States. It also participates in larger collaborations involving the U.S., the U.K., Spain, Germany, and France. Compared with other internationally collaborative output, these partnerships are producing papers with above average impact. Its research output shows a strong focus on Sustainable Development Goals (SDGs) Zero Hunger (SDG 2) and Life on Land (SDG 15), with impact for both around 0.7 to 0.8 times the world average. More broadly, Brazilian research output has a strong focus on the Life Sciences, while its output in Medicine has impact around 1.1 times the world average. Around 40% of output is published in open access (OA) journals, with their Humanities and Languages output 2.4 times more likely to be published in an OA journal than the G20 average. About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit About Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) is a consortium dedicated to expanding and strengthening postgraduate studies in Brazil. It ensures the quality of academic programs while fostering the development of highly qualified professionals in research, teaching, and other strategic scientific fields. Media contacts: Clarivate Rebecca KrahenbuhlSenior Manager, External Communications – Academia & Governmentnewsroom@ Catherine DanielDirector, External Communications – Life Sciences & Healthcarenewsroom@ CAPESJoão Mendes Communications View original content to download multimedia: SOURCE Clarivate Plc View original content to download multimedia:
Yahoo
29-05-2025
- Business
- Yahoo
ATS Corp (ATS) Q4 2025 Earnings Call Highlights: Record Order Backlog and Strategic Growth Amid ...
Order Bookings: $863 million in Q4, up 9% year-over-year; full-year bookings at $3.3 billion. Adjusted Revenues: $721 million in Q4, down 9% from the previous year. Adjusted Earnings from Operations: $74 million in Q4; $283 million for the full year. Order Backlog: Approximately $2.1 billion at the end of Q4. Book-to-Bill Ratio: 1.23:1 for the trailing 12 months. Gross Margin: 29% in Q4, a 90 basis point improvement from the previous year. SG&A Expenses: $133.9 million in Q4, an increase of $11.2 million year-over-year. Adjusted EPS: $0.41 in Q4. Cash Flows from Operating Activities: $39.3 million in Q4. CapEx and Intangible Investments: $29 million in Q4; $78.1 million for the full year. Net Debt to Adjusted EBITDA Ratio: 3.9 times at the end of Q4. Warning! GuruFocus has detected 8 Warning Signs with ATS. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ATS Corp (NYSE:ATS) reported a record order backlog of approximately $2.1 billion, the highest in the last 8 quarters, providing strong revenue visibility for fiscal 2026. The company achieved its finest bookings quarter in history, with order bookings for the quarter reaching $863 million, up 9% from the previous year. ATS Corp (NYSE:ATS) demonstrated strong performance in its Life Sciences segment, with a robust opportunity funnel supported by market growth in key submarkets. The company successfully negotiated a settlement with an EV customer, resulting in a significant cash inflow that will reduce net debt and provide greater financial flexibility. ATS Corp (NYSE:ATS) continues to expand its market reach and recurring revenue through strategic acquisitions, such as Paxiom and Heidolph, enhancing its product portfolio. Adjusted revenues for Q4 were down 9% year-over-year, primarily due to lower EV revenues, impacting overall financial performance. Geopolitical and trade tensions are creating an uncertain macroeconomic environment, which could potentially impact demand in some areas of ATS Corp (NYSE:ATS)'s business. The transportation segment experienced lower revenue volumes, contributing to a 23% decline in adjusted earnings from operations in Q4 compared to the prior year. ATS Corp (NYSE:ATS) faces challenges in managing working capital efficiency, particularly with the integration of recent acquisitions that are more working capital intensive. The company is navigating a complex tariff landscape, which requires ongoing efforts to mitigate risks and manage potential cost increases. Q: As you look at the backlog and the underlying duration of it, how confident do you feel about returning to positive organic growth in fiscal '26? A: Andrew Hider, CEO: We are very positive about returning to growth. Our trailing 12-month book-to-bill ratio of 1.23 supports this alignment, with all markets above 1. We are confident in the areas we are supporting and have seen continued investment from customers in strategic priorities. Overall, we are cautiously optimistic about the year. Q: Can you talk about the internal control deficiency noted and how it was identified? Was it related to the EV settlement accounting treatment? A: Ryan McLeod, CFO: It was identified through our normal course process, as this is our first year under SOCs requirements, which are more rigorous. It largely relates to documentation improvements needed around spreadsheets. Importantly, it had no impact on our financial statements, and we are focusing on addressing these documentation improvements in fiscal '26. Q: Can you provide color on the composition of programs within the healthcare backlog, particularly regarding the sustainability of GLP-1 growth? A: Andrew Hider, CEO: We are excited about our support in the GLP-1 space, working with 8+ customers. We view this as a short- to mid-term growth area. Beyond GLP-1, we are involved in radiopharmaceuticals, wearable devices, automated pharmacy, and contact lenses, which provide a diversified growth potential. Q: How should we think about working capital intensity and velocity of improvement, especially with the transportation business shrinking? A: Ryan McLeod, CFO: Excluding the EV settlement, our working capital is just over 15%. Transportation is more working capital intensive, but as it becomes a smaller part of our business, we see benefits. However, product-based businesses like Paxiom and Heidolph are more working capital intensive. Our target is to be below 15%, and we have initiatives to support this progress. Q: With the EV situation resolved, is it the right time to divest the EV business? A: Andrew Hider, CEO: The EV business has been rightsized to reflect current demand and is set up for success. Our work in this area is focused on factory automation, and with potential reshoring of manufacturing, there are opportunities in factory automation beyond this segment. We have good capabilities and can create value for customers and shareholders. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
ATS Corp (ATS) Q4 2025 Earnings Call Highlights: Record Order Backlog and Strategic Growth Amid ...
Order Bookings: $863 million in Q4, up 9% year-over-year; full-year bookings at $3.3 billion. Adjusted Revenues: $721 million in Q4, down 9% from the previous year. Adjusted Earnings from Operations: $74 million in Q4; $283 million for the full year. Order Backlog: Approximately $2.1 billion at the end of Q4. Book-to-Bill Ratio: 1.23:1 for the trailing 12 months. Gross Margin: 29% in Q4, a 90 basis point improvement from the previous year. SG&A Expenses: $133.9 million in Q4, an increase of $11.2 million year-over-year. Adjusted EPS: $0.41 in Q4. Cash Flows from Operating Activities: $39.3 million in Q4. CapEx and Intangible Investments: $29 million in Q4; $78.1 million for the full year. Net Debt to Adjusted EBITDA Ratio: 3.9 times at the end of Q4. Warning! GuruFocus has detected 8 Warning Signs with ATS. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ATS Corp (NYSE:ATS) reported a record order backlog of approximately $2.1 billion, the highest in the last 8 quarters, providing strong revenue visibility for fiscal 2026. The company achieved its finest bookings quarter in history, with order bookings for the quarter reaching $863 million, up 9% from the previous year. ATS Corp (NYSE:ATS) demonstrated strong performance in its Life Sciences segment, with a robust opportunity funnel supported by market growth in key submarkets. The company successfully negotiated a settlement with an EV customer, resulting in a significant cash inflow that will reduce net debt and provide greater financial flexibility. ATS Corp (NYSE:ATS) continues to expand its market reach and recurring revenue through strategic acquisitions, such as Paxiom and Heidolph, enhancing its product portfolio. Adjusted revenues for Q4 were down 9% year-over-year, primarily due to lower EV revenues, impacting overall financial performance. Geopolitical and trade tensions are creating an uncertain macroeconomic environment, which could potentially impact demand in some areas of ATS Corp (NYSE:ATS)'s business. The transportation segment experienced lower revenue volumes, contributing to a 23% decline in adjusted earnings from operations in Q4 compared to the prior year. ATS Corp (NYSE:ATS) faces challenges in managing working capital efficiency, particularly with the integration of recent acquisitions that are more working capital intensive. The company is navigating a complex tariff landscape, which requires ongoing efforts to mitigate risks and manage potential cost increases. Q: As you look at the backlog and the underlying duration of it, how confident do you feel about returning to positive organic growth in fiscal '26? A: Andrew Hider, CEO: We are very positive about returning to growth. Our trailing 12-month book-to-bill ratio of 1.23 supports this alignment, with all markets above 1. We are confident in the areas we are supporting and have seen continued investment from customers in strategic priorities. Overall, we are cautiously optimistic about the year. Q: Can you talk about the internal control deficiency noted and how it was identified? Was it related to the EV settlement accounting treatment? A: Ryan McLeod, CFO: It was identified through our normal course process, as this is our first year under SOCs requirements, which are more rigorous. It largely relates to documentation improvements needed around spreadsheets. Importantly, it had no impact on our financial statements, and we are focusing on addressing these documentation improvements in fiscal '26. Q: Can you provide color on the composition of programs within the healthcare backlog, particularly regarding the sustainability of GLP-1 growth? A: Andrew Hider, CEO: We are excited about our support in the GLP-1 space, working with 8+ customers. We view this as a short- to mid-term growth area. Beyond GLP-1, we are involved in radiopharmaceuticals, wearable devices, automated pharmacy, and contact lenses, which provide a diversified growth potential. Q: How should we think about working capital intensity and velocity of improvement, especially with the transportation business shrinking? A: Ryan McLeod, CFO: Excluding the EV settlement, our working capital is just over 15%. Transportation is more working capital intensive, but as it becomes a smaller part of our business, we see benefits. However, product-based businesses like Paxiom and Heidolph are more working capital intensive. Our target is to be below 15%, and we have initiatives to support this progress. Q: With the EV situation resolved, is it the right time to divest the EV business? A: Andrew Hider, CEO: The EV business has been rightsized to reflect current demand and is set up for success. Our work in this area is focused on factory automation, and with potential reshoring of manufacturing, there are opportunities in factory automation beyond this segment. We have good capabilities and can create value for customers and shareholders. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Irish Times
25-05-2025
- Business
- Irish Times
Venture capital funding surges to record in first quarter
Irish small and medium business raised a record €533 million in venture capital in the first quarter of the year. But the figures from the Irish Venture Capital Association (IVCA) highlight an imbalance in the market, with the quarter dominated by larger deals and things looking less positive for smaller companies looking to raise less than €3 million. The life sciences sector was most in demand with funders, accounting for 45 per cent of the funding total in the quarter, according to the VenturePulse survey. That was followed by cybersecurity at 22 per cent, software at 9 per cent and fintech at 8 per cent. AI and machine learning accounted for 7 per cent. Among the five biggest deals were the €150 million raised by life sciences company Let's Get Checked, and the €115 million raised by cybersecurity company Tines. AI company, Protex AI, drone delivery firm, Manna, and medical technology manufacturer, Perfuze, completed the top five. READ MORE More than 80 per cent of the deal value was down to deals worth more than €10 million. Among individual deals, those in the €30 million and over category rose by almost 90 per cent to reach €296.8 million, while deals in the €10 million to €30 million range were up 184 per cent to €132 million. But while deals for more than €3 million in funding rose, those in the €1 million to €3 million category were down 5 per cent to €21.6 million, and those under €1 million were down 42 per cent to €3.6 million. Seed funding was also lower, falling 3 per cent. Overseas investors played a significant role in funding during the quarter, at 82 per cent compared to 71 per cent a year earlier. 'This is a doubled edged sword,' said Sarah-Jane Larkin, director general of the IVCA. 'While it reflects the high quality and potential of Irish tech firms and demand by overseas investors, it also reflects Ireland Inc's vulnerability to international influences if the tide goes out.' That is of particular concern given the tariffs introduced by US president Donald Trump and others threatened, which have injected considerable uncertainty into the global markets. The venture capital figures cover the period before US 'liberation day' on April 2nd. Gerry Maguire, chairman of the IVCA, said there was anecdotal evidence that uncertainty and caution is likely to show up in following quarters, especially among overseas investors. The VenturePulse survey is compiled from information supplied internally by members of the IVCA and from published information where the funding included non-IVCA members.
